US FDA declines to approve Atara Biotherapeutics' cancer therapy

Atara Biotherapeutics

16/01/2025 13:36

Jan 16 (Reuters) - The U.S. Food and Drug Administration
on Thursday declined to approve Atara Biotherapeutics'  ATRA.O 
cancer therapy, chemically called tabelecleucel.
    The company was seeking approval for the therapy to treat
patients with Epstein-Barr virus positive post-transplant
lymphoproliferative disease (EBV+ PTLD). 
    

 (Reporting by Kamal Choudhury and Christy Santhosh in
Bengaluru; Editing by Shilpi Majumdar)
 ((Kamal.Choudhury@thomsonreuters.com))